Allogene Therapeutics, Inc. (ALLO) Net income 2018–2025
Allogene Therapeutics, Inc. (ALLO) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$190.9MFY2025 · since FY2018: -$211.5M → -$190.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$190.9M | +25.9% |
| FY2024 | -$257.6M | +21.3% |
| FY2023 | -$327.3M | +3.9% |
| FY2022 | -$340.4M | -87.0% |
| FY2021 | -$182.1M | +42.5% |
| FY2020 | -$316.4M | -71.4% |
| FY2019 | -$184.6M | +12.7% |
| FY2018 | -$211.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALLO financial trends
ALLO RevenueALLO Net marginALLO Gross profitALLO Gross marginALLO Operating incomeALLO Operating marginALLO Operating cash flowALLO Free cash flowALLO Capital expendituresALLO Return on equityALLO Stock buybacksALLO Dividends paidALLO Total assetsALLO Total liabilitiesALLO Shareholders’ equityALLO overview →